Gene Expression Atlas home | about the project | faq | feedback | blog | das | api | help
PDCD1
REST API REST API
Homo sapiens
PDCD1 is differentially expressed in 152 experiments: 66 organism parts: uterus, lung, ... (64 more);, 122 disease states: normal, chronic lymphocytic leukemia, ... (120 more);, 37 cell types 105 cell lines 18 compound treatments and 59 other conditions.
Synonyms CD279, PD1
Orthologs PDCD1 (Gallus gallus)   Pdcd1 (Mus musculus)   A4FV85_BOVIN (Bos taurus)   Pdcd1 (Rattus norvegicus)   PDCD1 (Canis familiaris)   (Compare orthologs)
Gene Ontology Term humoral immune response, plasma membrane, protein binding, apoptosis, signal transducer activity, external side of plasma membrane, protein tyrosine phosphatase activity, multicellular organismal development, integral to membrane, signal transduction, peptidyl-tyrosine dephosphorylation, T cell costimulation
InterPro Term Ig_V-set, Ig_sub, Ig-like, Ig_V-set_subgr
UniProt Accession Q15116, Q8IX89, Q86TL7, F5GX22, E7ER21
Gene-Disease Assocation AUTOIMMUNE DISEASE, MULTIPLE SCLEROSIS, SUSCEPTIBILITY TO; MS, SYSTEMIC LUPUS ERYTHEMATOSUS; SLE, SYSTEMIC LUPUS ERYTHEMATOSUS, SUSCEPTIBILITY TO, 2; SLEB2
Search EB-eye ENSG00000188389
Show more properties
Experimental Factors
Organism part

studied in E-GEOD-15765, E-AFMX-5, E-GEOD-803, E-MTAB-24, E-MTAB-25, ... (19 experiments)

3
1
Number of published studies where the gene is over/under expressed compared to the gene's overall mean expression level in the study.

anatomogram

Cell line

studied in E-GEOD-17482, E-GEOD-19639, E-GEOD-22639, E-GEOD-2450, E-GEOD-24147, ... (15 experiments)

Factor Value U/D Experiments
MOLT4
2
E-MTAB-62, E-MTAB-37
SW480
2
E-MEXP-1014, E-MTAB-37
HL-60
1
E-GEOD-24147
L428
1
E-MTAB-37
TT
1
E-MTAB-37
mcf10a-myc cells
1
E-MTAB-62
99 more value(s).


Cell type

studied in E-GEOD-10797, E-GEOD-18811, E-AFMX-5, E-MTAB-25, E-GEOD-20033, ... (24 experiments)

Factor Value U/D Experiments
CD4+ T cell
7
2
E-GEOD-16190, E-AFMX-5
CD14+ monocyte
2
1
E-MEXP-1600
CD4 positive T-cell
1
E-GEOD-6338
parental foreskin cells
1
E-GEOD-20033
embryonic stem cell
1
E-GEOD-26672
Monocytes
1
E-GEOD-21909
31 more value(s).


Disease state

studied in E-GEOD-3307, E-GEOD-15960, E-GEOD-2466, E-GEOD-1869, E-MEXP-2069, ... (32 experiments)

Factor Value U/D Experiments
acute promyelocytic leukemia
2
E-GEOD-1729, E-MTAB-62
chronic lymphocytic leukemia
1
2
E-GEOD-2466, E-MTAB-37, E-GEOD-6691
presymptomatic DMD
1
E-MTAB-62
Emery-Dreifuss muscular dystrophy
1
E-GEOD-3307
hereditary leiomyomatosis and renal cell cancer
1
E-MTAB-62
colon cancer
1
E-MTAB-62
116 more value(s).


Compound treatment

studied in E-GEOD-3284, E-GEOD-412, E-GEOD-697, E-MEXP-2345, E-GEOD-2803, ... (10 experiments)

Factor Value U/D Experiments
U0126
1
E-GEOD-697
estradiol
1
E-GEOD-20081
tBHP
1
E-MEXP-2345
all-trans retinoic acid
1
1
E-GEOD-995
bacterial endotoxin
1
1
E-GEOD-3284
phoshate buffered saline
1
E-GEOD-3720
12 more value(s).


Age at onset

studied in E-GEOD-21521

Factor Value U/D Experiments
not specified
1
E-GEOD-21521


Agent
studied in E-GEOD-19519

Biopsy tissue
studied in E-GEOD-5851

Biosource provider
studied in E-MTAB-37

BioSourceProvider
studied in E-GEOD-19466, E-GEOD-19519, E-GEOD-19480

Blood/non-blood meta-groups
studied in E-MTAB-62

Bmngrd
studied in E-GEOD-20194, E-GEOD-16716

Cancer site
studied in E-GEOD-4271

Chromosomal aberration
studied in E-GEOD-1729

Clinical history
studied in E-GEOD-19743, E-GEOD-7967, E-GEOD-21589, E-GEOD-16363, E-GEOD-512, ... (6 experiments)

Clinical info
studied in E-GEOD-19743, E-GEOD-21589, E-GEOD-16363

Clinical treatment
studied in E-GEOD-1743, E-GEOD-6532

coriell cell line repository identifier
studied in E-GEOD-19519

Developmental stage
studied in E-MTAB-62

Disease staging
studied in E-GEOD-89, E-GEOD-19743, E-GEOD-3325

Environmental stress
studied in E-GEOD-1518, E-GEOD-3720

Epiregulin elisa conc ng ml
studied in E-GEOD-5851

Er
studied in E-GEOD-20194, E-GEOD-16716

Estrogen receptor status
studied in E-GEOD-6532

Ethnic group
studied in E-GEOD-20194, E-GEOD-16716

family id
studied in E-GEOD-19519

Genetic modification
studied in E-GEOD-8023, E-GEOD-6431

Genotype
studied in E-GEOD-22056, E-GEOD-2466, E-GEOD-17476, E-TABM-321

369 groups
studied in E-MTAB-62

4 groups from blood to incompletely diff
studied in E-MTAB-62

96 groups
studied in E-MTAB-62

Growth condition
studied in E-TABM-263, E-MEXP-1446, E-GEOD-22278

Her2 ihc
studied in E-GEOD-20194, E-GEOD-16716

Histology
studied in E-GEOD-21653, E-TABM-276

Individual
studied in E-MTAB-197, E-TABM-325, E-GEOD-2466, E-MEXP-2069, E-GEOD-1926, ... (21 experiments)

Infection
studied in E-GEOD-2405, E-GEOD-12108, E-GEOD-12254, E-MEXP-561

Injury
studied in E-GEOD-19743

Material type
studied in E-MEXP-958, E-GEOD-9171

15 meta groups
studied in E-MTAB-62

4 meta groups
studied in E-MTAB-62

6 meta groups
studied in E-MTAB-62

Metastasis
studied in E-GEOD-18105

Molecular subtype
studied in E-GEOD-21653

Organism
studied in E-GEOD-7540

Original diagnosis
studied in E-GEOD-21521

Performer
studied in E-GEOD-2004, E-LGCL-5

Phenotype
studied in E-GEOD-1309, E-GEOD-1657

Population
studied in E-MTAB-197, E-GEOD-4922, E-GEOD-4342

Progesterone receptor status
studied in E-GEOD-6532

Progression free survival of days
studied in E-GEOD-5851

Protocol type
studied in E-GEOD-3254

pt
studied in E-GEOD-21653

RNAi
studied in E-MEXP-1509, E-MEXP-101

Sample preparation
studied in E-GEOD-16728, E-GEOD-12710

sampleID
studied in E-GEOD-24283

Sampling time point
studied in E-GEOD-19743, E-GEOD-21374

Sex
studied in E-GEOD-2466

Stimulation
studied in E-GEOD-20114, E-GEOD-11428

Survival time
studied in E-GEOD-3494

Test result
studied in E-GEOD-1926

Treatment
studied in E-GEOD-22369, E-GEOD-22368, E-GEOD-16837, E-GEOD-19246

Treatment code
studied in E-GEOD-20194, E-GEOD-16716

Treatments comments
studied in E-GEOD-20194, E-GEOD-16716

Tumor size
studied in E-GEOD-3494

Processing time: 0.387 secs.
 
Gene Expression Atlas 2.0.11.1- 12/23/11 3:09:34 PM